6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
described O
in O
detail O
in O
other O
labeling O
sections O
: O
* O
Teratogenicity B-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.1 O
, O
5.2 O
) O
, O
and O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
* O
Venous B-OSE_Labeled_AE
and I-OSE_Labeled_AE
Arterial I-OSE_Labeled_AE
Thromboembolism I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.3 O
) O
, O
and O
Patient O
Counseling O
Information O
( O
17 O
) O
] O
* O
Increased O
Mortality B-NonOSE_AE
in O
Patients O
with O
MM O
When O
Pembrolizumab O
Is O
Added O
to O
a O
Thalidomide O
Analogue O
and O
Dexamethasone O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Drowsiness B-OSE_Labeled_AE
and O
Somnolence B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Peripheral B-OSE_Labeled_AE
Neuropathy I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Dizziness B-OSE_Labeled_AE
and O
Orthostatic B-OSE_Labeled_AE
Hypotension I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Neutropenia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Thrombocytopenia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Increased B-OSE_Labeled_AE
HIV I-OSE_Labeled_AE
Viral I-OSE_Labeled_AE
Load I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
* O
Bradycardia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
* O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
and O
Toxic B-OSE_Labeled_AE
Epidermal I-OSE_Labeled_AE
Necrolysis I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.12 O
) O
] O
* O
Seizures B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.13 O
) O
] O
* O
Tumor B-OSE_Labeled_AE
Lysis I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.14 O
) O
] O
* O
Hypersensitivity B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.16 O
) O
] O
* O
MM B-Not_AE_Candidate
: O
The O
most O
common O
adverse O
reactions O
( O
> O
= O
20 O
% O
) O
are O
fatigue B-OSE_Labeled_AE
, O
hypocalcemia B-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
neuropathy B-OSE_Labeled_AE
- I-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
/ O
desquamation B-OSE_Labeled_AE
, O
confusion B-OSE_Labeled_AE
, O
anorexia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
/ O
agitation B-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
thrombosis B-OSE_Labeled_AE
/ O
embolism B-OSE_Labeled_AE
, O
neuropathy B-OSE_Labeled_AE
- I-OSE_Labeled_AE
motor I-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
and O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
. O

( O
6.1 O
) O
* O
ENL B-Not_AE_Candidate
: O
The O
most O
common O
adverse O
reactions O
( O
> O
= O
10 O
% O
) O
are O
somnolence B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
and O
headache B-OSE_Labeled_AE
. O

( O
6.1 O
) O
EXCERPT O
: O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
or O
embryo-fetal O
exposure O
: O
contact O
Celgene O
Corporation O
at O
1-888-423-5436 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

Most O
patients O
taking O
thalidomide O
can O
be O
expected O
to O
experience O
adverse O
reactions O
. O

Teratogenicity O
: O
The O
most O
serious O
toxicity O
associated O
with O
thalidomide O
is O
its O
documented O
human B-OSE_Labeled_AE
teratogenicity I-OSE_Labeled_AE
. O

The O
risk O
of O
severe O
birth B-OSE_Labeled_AE
defects I-OSE_Labeled_AE
, O
primarily O
phocomelia B-OSE_Labeled_AE
or O
death B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
, O
is O
extremely O
high O
during O
the O
critical O
period O
of O
pregnancy B-Not_AE_Candidate
. O

The O
critical O
period O
is O
estimated O
, O
depending O
on O
the O
source O
of O
information O
, O
to O
range O
from O
35 O
to O
50 O
days O
after O
the O
last O
menstrual O
period O
. O

The O
risk O
of O
other O
potentially O
severe O
birth B-NonOSE_AE
defects I-NonOSE_AE
outside O
this O
critical O
period O
is O
unknown O
, O
but O
may O
be O
significant O
. O

Based O
on O
present O
knowledge O
, O
thalidomide O
must O
not O
be O
used O
at O
any O
time O
during O
pregnancy B-Not_AE_Candidate
. O

Because O
thalidomide O
is O
present O
in O
the O
semen O
of O
patients O
receiving O
the O
drug O
, O
males O
receiving O
thalidomide O
must O
always O
use O
a O
latex O
or O
synthetic O
condom O
during O
any O
sexual O
contact O
with O
females O
of O
reproductive O
potential O
, O
even O
if O
he O
has O
undergone O
a O
successful O
vasectomy O
. O

Venous O
and O
Arterial B-OSE_Labeled_AE
Thromboembolism I-OSE_Labeled_AE
: O
An O
increased O
risk O
of O
venous B-OSE_Labeled_AE
thromboembolism I-OSE_Labeled_AE
( O
such O
as O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
and O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
) O
, O
ischemic B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
( O
including O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
) O
, O
and O
stroke B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
with O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
treated O
with O
thalidomide O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

Peripheral O
Neuropathy O
: O
Peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
is O
a O
very O
common O
, O
potentially O
severe O
, O
adverse O
reaction O
of O
treatment O
with O
thalidomide O
that O
may O
result O
in O
irreversible O
damage O
. O

Peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
generally O
occurs O
following O
chronic O
use O
over O
a O
period O
of O
months O
. O

However O
, O
reports O
following O
relatively O
short-term O
use O
also O
exist O
. O

Incidence O
of O
neuropathy B-OSE_Labeled_AE
events O
leading O
to O
discontinuation O
, O
dose O
reduction O
or O
interruption O
increases O
with O
cumulative O
dose O
and O
duration O
of O
therapy O
. O

Symptoms O
may O
occur O
some O
time O
after O
thalidomide O
treatment O
has O
been O
stopped O
and O
may O
resolve O
slowly O
or O
not O
at O
all O
. O

Somnolence B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
and O
rash B-OSE_Labeled_AE
are O
the O
most O
commonly O
observed O
adverse O
reactions O
associated O
with O
the O
use O
of O
thalidomide O
. O

Adverse O
event O
profiles O
from O
clinical O
trials O
are O
summarized O
in O
the O
sections O
that O
follow O
. O

Adverse O
Reactions O
in O
Multiple O
Myeloma O
Controlled O
Clinical O
Trials O
The O
safety O
analyses O
were O
conducted O
in O
two O
controlled O
clinical O
studies O
( O
Study O
1 O
and O
Study O
2 O
) O
. O

The O
safety O
analysis O
in O
Study O
1 O
was O
conducted O
on O
204 O
patients O
who O
received O
treatment O
. O

Table O
1 O
lists O
the O
most O
common O
adverse O
drug O
reactions O
( O
> O
= O
10 O
% O
) O
. O

The O
most O
frequently O
reported O
adverse O
reactions O
were O
fatigue B-OSE_Labeled_AE
, O
hypocalcemia B-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
sensory B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
/ O
desquamation B-OSE_Labeled_AE
, O
confusion B-OSE_Labeled_AE
, O
anorexia B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
/ O
agitation B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
thrombosis B-OSE_Labeled_AE
/ O
embolism B-OSE_Labeled_AE
, O
neuropathy B-OSE_Labeled_AE
- I-OSE_Labeled_AE
motor I-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
and O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
. O

Twenty-three O
percent O
of O
patients O
( O
47/204 O
) O
discontinued O
due O
to O
adverse O
reactions O
; O
30 O
% O
( O
31/102 O
) O
from O
the O
THALOMID/dexamethasone O
arm O
and O
16 O
% O
( O
16/102 O
) O
from O
the O
dexamethasone O
alone O
arm O
. O

Table O
1 O
: O
Adverse O
Drug O
Reactions O
Reported O
in O
> O
=10 O
% O
of O
Patients O
in O
the O
THALOMID/Dexamethasone O
Arm O
( O
Study O
1 O
- O
Safety O
Population O
; O
N=204 O
) O
*Treatment-emergent O
adverse O
reactions O
reported O
in O
> O
=10 O
% O
of O
patients O
in O
THALOMID/dexamethasone O
arm O
and O
with O
a O
> O
=1 O
% O
difference O
in O
the O
THALOMID/dexamethasone O
arm O
compared O
to O
the O
dexamethasone O
alone O
arm O
. O

Body O
SystemAdverse O
Reaction O
Thal O
+ O
Dex O
* O
( O
N=102 O
) O
Dex O
Alone* O
( O
N=102 O
) O
All O
Gradesn O
( O
% O
) O
Grade O
3/4n O
( O
% O
) O
All O
Gradesn O
( O
% O
) O
Grade O
3/4n O
( O
% O
) O
Metabolic B-NonOSE_AE
/ I-NonOSE_AE
Laboratory I-NonOSE_AE
97 O
( O
95 O
) O
33 O
( O
32 O
) O
96 O
( O
94 O
) O
30 O
( O
29 O
) O
Hypocalcemia B-OSE_Labeled_AE
73 O
( O
72 O
) O
11 O
( O
11 O
) O
60 O
( O
59 O
) O
5 O
( O
5 O
) O
Neurology B-NonOSE_AE
92 O
( O
90 O
) O
30 O
( O
29 O
) O
76 O
( O
74 O
) O
18 O
( O
18 O
) O
Neuropathy B-OSE_Labeled_AE
- I-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
55 O
( O
54 O
) O
4 O
( O
4 O
) O
28 O
( O
28 O
) O
1 O
( O
1 O
) O
Confusion B-OSE_Labeled_AE
29 O
( O
28 O
) O
9 O
( O
9 O
) O
12 O
( O
12 O
) O
3 O
( O
3 O
) O
Anxiety B-OSE_Labeled_AE
/ O
agitation B-OSE_Labeled_AE
26 O
( O
26 O
) O
1 O
( O
1 O
) O
14 O
( O
14 O
) O
3 O
( O
3 O
) O
Tremor B-OSE_Labeled_AE
26 O
( O
26 O
) O
1 O
( O
1 O
) O
6 O
( O
6 O
) O
0 O
( O
0 O
) O
Neuropathy B-OSE_Labeled_AE
- I-OSE_Labeled_AE
motor I-OSE_Labeled_AE
22 O
( O
22 O
) O
8 O
( O
8 O
) O
16 O
( O
16 O
) O
5 O
( O
5 O
) O
Dizziness B-OSE_Labeled_AE
/ O
lightheadedness B-OSE_Labeled_AE
20 O
( O
20 O
) O
1 O
( O
1 O
) O
14 O
( O
14 O
) O
0 O
( O
0 O
) O
Depressed B-OSE_Labeled_AE
level I-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
16 O
( O
16 O
) O
3 O
( O
3 O
) O
3 O
( O
3 O
) O
3 O
( O
3 O
) O
Constitutional B-NonOSE_AE
Symptoms I-NonOSE_AE
91 O
( O
89 O
) O
19 O
( O
19 O
) O
84 O
( O
82 O
) O
16 O
( O
16 O
) O
Fatigue B-OSE_Labeled_AE
81 O
( O
79 O
) O
17 O
( O
17 O
) O
72 O
( O
71 O
) O
13 O
( O
13 O
) O
Fever B-OSE_Labeled_AE
24 O
( O
24 O
) O
1 O
( O
1 O
) O
20 O
( O
20 O
) O
3 O
( O
3 O
) O
Weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
23 O
( O
23 O
) O
1 O
( O
1 O
) O
21 O
( O
21 O
) O
2 O
( O
2 O
) O
Weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
22 O
( O
22 O
) O
1 O
( O
1 O
) O
13 O
( O
13 O
) O
0 O
( O
0 O
) O
Blood B-NonOSE_AE
/ I-NonOSE_AE
Bone I-NonOSE_AE
Marrow I-NonOSE_AE
88 O
( O
86 O
) O
29 O
( O
29 O
) O
96 O
( O
94 O
) O
19 O
( O
19 O
) O
Leukocytes B-OSE_Labeled_AE
( I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
) O
36 O
( O
35 O
) O
6 O
( O
6 O
) O
30 O
( O
29 O
) O
3 O
( O
3 O
) O
Neutrophils B-OSE_Labeled_AE
( I-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
) O
32 O
( O
31 O
) O
10 O
( O
10 O
) O
24 O
( O
24 O
) O
10 O
( O
10 O
) O
Gastrointestinal B-NonOSE_AE
83 O
( O
81 O
) O
22 O
( O
22 O
) O
70 O
( O
69 O
) O
8 O
( O
8 O
) O
Constipation B-OSE_Labeled_AE
56 O
( O
55 O
) O
8 O
( O
8 O
) O
29 O
( O
28 O
) O
1 O
( O
1 O
) O
Anorexia B-OSE_Labeled_AE
29 O
( O
28 O
) O
4 O
( O
4 O
) O
25 O
( O
24 O
) O
2 O
( O
2 O
) O
Nausea B-OSE_Labeled_AE
29 O
( O
28 O
) O
5 O
( O
5 O
) O
23 O
( O
22 O
) O
1 O
( O
1 O
) O
Mouth B-OSE_Labeled_AE
dryness I-OSE_Labeled_AE
12 O
( O
12 O
) O
1 O
( O
1 O
) O
6 O
( O
6 O
) O
0 O
( O
0 O
) O
Cardiovascular B-NonOSE_AE
70 O
( O
69 O
) O
37 O
( O
36 O
) O
60 O
( O
59 O
) O
21 O
( O
21 O
) O
Edema B-OSE_Labeled_AE
58 O
( O
56 O
) O
6 O
( O
6 O
) O
47 O
( O
46 O
) O
4 O
( O
4 O
) O
Thrombosis B-OSE_Labeled_AE
/ O
embolism B-OSE_Labeled_AE
23 O
( O
22 O
) O
21 O
( O
21 O
) O
5 O
( O
5 O
) O
5 O
( O
5 O
) O
Pain B-OSE_Labeled_AE
64 O
( O
63 O
) O
10 O
( O
10 O
) O
66 O
( O
65 O
) O
15 O
( O
15 O
) O
Myalgia B-OSE_Labeled_AE
17 O
( O
17 O
) O
0 O
( O
0 O
) O
14 O
( O
14 O
) O
1 O
( O
1 O
) O
Arthralgia B-OSE_Labeled_AE
13 O
( O
13 O
) O
0 O
( O
0 O
) O
10 O
( O
10 O
) O
2 O
( O
2 O
) O
Pulmonary B-NonOSE_AE
52 O
( O
51 O
) O
19 O
( O
19 O
) O
51 O
( O
50 O
) O
20 O
( O
20 O
) O
Dyspnea B-OSE_Labeled_AE
43 O
( O
42 O
) O
13 O
( O
13 O
) O
32 O
( O
31 O
) O
15 O
( O
15 O
) O
Dermatology B-NonOSE_AE
/ I-NonOSE_AE
Skin I-NonOSE_AE
48 O
( O
47 O
) O
5 O
( O
5 O
) O
35 O
( O
34 O
) O
2 O
( O
2 O
) O
Rash B-OSE_Labeled_AE
/ O
desquamation B-OSE_Labeled_AE
31 O
( O
30 O
) O
4 O
( O
4 O
) O
18 O
( O
18 O
) O
2 O
( O
2 O
) O
Dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
21 O
( O
21 O
) O
0 O
( O
0 O
) O
11 O
( O
11 O
) O
0 O
( O
0 O
) O
Hepatic B-NonOSE_AE
47 O
( O
46 O
) O
7 O
( O
7 O
) O
45 O
( O
44 O
) O
4 O
( O
4 O
) O
Bilirubin B-OSE_Labeled_AE
14 O
( O
14 O
) O
2 O
( O
2 O
) O
10 O
( O
10 O
) O
2 O
( O
2 O
) O
Musculoskeletal B-NonOSE_AE
42 O
( O
41 O
) O
9 O
( O
9 O
) O
41 O
( O
40 O
) O
14 O
( O
14 O
) O
Muscle B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
41 O
( O
40 O
) O
6 O
( O
6 O
) O
38 O
( O
37 O
) O
13 O
( O
13 O
) O
The O
safety O
analysis O
in O
Study O
2 O
was O
conducted O
on O
466 O
patients O
who O
received O
treatment O
. O

Table O
2 O
lists O
the O
most O
common O
adverse O
drug O
reactions O
( O
> O
= O
10 O
% O
) O
that O
were O
observed O
. O

Table O
3 O
lists O
the O
most O
common O
Grade O
3/4 O
adverse O
drug O
reactions O
( O
occurring O
at O
> O
2 O
% O
) O
that O
were O
observed O
. O

The O
adverse O
reactions O
most O
often O
reported O
by O
patients O
treated O
with O
THALOMID/dexamethasone O
were O
constipation B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
asthenia B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
and O
fatigue B-OSE_Labeled_AE
. O

Adverse O
reactions O
with O
a O
frequency O
at O
least O
2-fold O
higher O
in O
the O
THALOMID/dexamethasone O
group O
than O
in O
the O
placebo/dexamethasone O
group O
include O
constipation B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
and O
peripheral B-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
. O

Twenty-six O
percent O
of O
patients O
( O
121/466 O
) O
discontinued O
due O
to O
adverse O
events O
; O
37 O
% O
( O
86/234 O
) O
from O
the O
THALOMID/dexamethasone O
arm O
and O
15 O
% O
( O
35/232 O
) O
from O
the O
placebo/dexamethasone O
arm O
. O

Table O
2 O
: O
Adverse O
Drug O
Reactions O
Reported O
in O
> O
=10 O
% O
of O
Patients O
in O
the O
THALOMID/Dexamethasone O
Arm O
( O
Study O
2 O
- O
Safety O
Population O
; O
N=466 O
) O
*All O
adverse O
reactions O
reported O
in O
> O
=10 O
% O
of O
patients O
in O
THALOMID/dexamethasone O
arm O
and O
with O
a O
> O
=1 O
% O
difference O
in O
proportion O
of O
patients O
between O
the O
THALOMID/dexamethasone O
arm O
compared O
to O
the O
placebo/dexamethasone O
arm O
. O

NOS O
= O
not O
otherwise O
specified O
. O

Body O
SystemAdverse O
Reaction O
Thal/Dex O
( O
N=234 O
) O
*n O
( O
% O
) O
Placebo/Dex O
( O
N=232 O
) O
*n O
( O
% O
) O
Patients O
with O
at O
least O
1 O
Adverse O
Reaction O
233 O
( O
99 O
) O
230 O
( O
99 O
) O
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
176 O
( O
75 O
) O
149 O
( O
64 O
) O
Edema B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
80 O
( O
34 O
) O
57 O
( O
25 O
) O
Asthenia B-OSE_Labeled_AE
56 O
( O
24 O
) O
47 O
( O
20 O
) O
Fatigue B-OSE_Labeled_AE
50 O
( O
21 O
) O
36 O
( O
16 O
) O
Edema B-OSE_Labeled_AE
NOS O
31 O
( O
13 O
) O
19 O
( O
8 O
) O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
162 O
( O
69 O
) O
149 O
( O
64 O
) O
Constipation B-OSE_Labeled_AE
116 O
( O
50 O
) O
49 O
( O
21 O
) O
Nausea B-OSE_Labeled_AE
30 O
( O
13 O
) O
27 O
( O
12 O
) O
Dyspepsia B-OSE_Labeled_AE
27 O
( O
11 O
) O
21 O
( O
9 O
) O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
161 O
( O
69 O
) O
138 O
( O
60 O
) O
Tremor B-OSE_Labeled_AE
62 O
( O
26 O
) O
29 O
( O
12 O
) O
Dizziness B-OSE_Labeled_AE
51 O
( O
23 O
) O
32 O
( O
14 O
) O
Paresthesia B-OSE_Labeled_AE
27 O
( O
12 O
) O
15 O
( O
6 O
) O
Peripheral B-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
24 O
( O
10 O
) O
12 O
( O
5 O
) O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
139 O
( O
59 O
) O
138 O
( O
60 O
) O
Pneumonia B-OSE_Labeled_AE
NOS O
35 O
( O
15 O
) O
28 O
( O
12 O
) O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
90 O
( O
38 O
) O
97 O
( O
42 O
) O
Anxiety B-OSE_Labeled_AE
27 O
( O
12 O
) O
22 O
( O
10 O
) O
Depression B-OSE_Labeled_AE
24 O
( O
10 O
) O
19 O
( O
8 O
) O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
96 O
( O
41 O
) O
89 O
( O
38 O
) O
Hyperglycemia B-OSE_Labeled_AE
NOS O
36 O
( O
15 O
) O
32 O
( O
14 O
) O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
92 O
( O
39 O
) O
53 O
( O
23 O
) O
Deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
30 O
( O
13 O
) O
4 O
( O
2 O
) O
Table O
3 O
: O
Grade O
3/4 O
Adverse O
Drug O
Reactions O
Reported O
in O
> O
2 O
% O
of O
Patients O
in O
the O
THALOMID/Dexamethasone O
Arm O
( O
Study O
2 O
- O
Safety O
Population O
; O
N=466 O
) O
*All O
Grade O
3/4 O
adverse O
reactions O
with O
> O
2 O
% O
of O
patients O
in O
THALOMID/dexamethasone O
arm O
and O
with O
a O
higher O
frequency O
in O
the O
THALOMID/dexamethasone O
arm O
compared O
to O
the O
placebo/dexamethasone O
arm O
. O

NOS O
= O
not O
otherwise O
specified O
. O

Body O
SystemAdverse O
Reaction O
THALOMID/Dex O
( O
N=234 O
) O
*n O
( O
% O
) O
Placebo/Dex O
( O
N=232 O
) O
*n O
( O
% O
) O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
50 O
( O
21 O
) O
36 O
( O
16 O
) O
Pneumonia B-OSE_Labeled_AE
NOS O
17 O
( O
7 O
) O
14 O
( O
6 O
) O
Bronchopneumonia B-OSE_Labeled_AE
NOS O
7 O
( O
3 O
) O
3 O
( O
1 O
) O
General B-NonOSE_AE
Disorders I-NonOSE_AE
andAdministration I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
44 O
( O
19 O
) O
26 O
( O
11 O
) O
Asthenia B-OSE_Labeled_AE
11 O
( O
5 O
) O
4 O
( O
2 O
) O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
NutritionDisorders I-NonOSE_AE
33 O
( O
14 O
) O
34 O
( O
15 O
) O
Hypokalemia B-OSE_Labeled_AE
7 O
( O
3 O
) O
3 O
( O
1 O
) O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
47 O
( O
20 O
) O
20 O
( O
9 O
) O
Syncope B-OSE_Labeled_AE
8 O
( O
3 O
) O
1 O
( O
< O
1 O
) O
Peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
NOS O
8 O
( O
3 O
) O
0 O
( O
0 O
) O
Cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
6 O
( O
3 O
) O
1 O
( O
< O
1 O
) O
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
35 O
( O
15 O
) O
27 O
( O
11 O
) O
Atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
11 O
( O
5 O
) O
8 O
( O
3 O
) O
Myocardial B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
6 O
( O
3 O
) O
2 O
( O
1 O
) O
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
42 O
( O
18 O
) O
14 O
( O
6 O
) O
Deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
27 O
( O
12 O
) O
4 O
( O
2 O
) O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
26 O
( O
11 O
) O
22 O
( O
10 O
) O
Constipation B-OSE_Labeled_AE
7 O
( O
3 O
) O
2 O
( O
1 O
) O
Investigations B-NonOSE_AE
21 O
( O
9 O
) O
21 O
( O
9 O
) O
Weight B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
8 O
( O
3 O
) O
4 O
( O
2 O
) O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
SystemDisorders I-NonOSE_AE
24 O
( O
10 O
) O
17 O
( O
7 O
) O
Neutropenia B-OSE_Labeled_AE
8 O
( O
3 O
) O
6 O
( O
3 O
) O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
, I-NonOSE_AE
andMediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
27 O
( O
12 O
) O
13 O
( O
6 O
) O
Pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
16 O
( O
7 O
) O
4 O
( O
2 O
) O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
19 O
( O
8 O
) O
8 O
( O
3 O
) O
Anxiety B-OSE_Labeled_AE
5 O
( O
2 O
) O
3 O
( O
1 O
) O
Confusional B-OSE_Labeled_AE
state I-OSE_Labeled_AE
5 O
( O
2 O
) O
2 O
( O
1 O
) O
Ear B-NonOSE_AE
and I-NonOSE_AE
Labyrinth I-NonOSE_AE
Disorders I-NonOSE_AE
6 O
( O
3 O
) O
0 O
( O
0 O
) O
Vertigo B-OSE_Labeled_AE
5 O
( O
2 O
) O
0 O
( O
0 O
) O
Less O
Common O
Adverse O
Drug O
Reactions O
in O
Multiple O
Myeloma O
Controlled O
Clinical O
Trials O
In O
Study O
2 O
, O
THALOMID O
in O
combination O
with O
dexamethasone O
in O
patients O
with O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
, O
the O
following O
adverse O
drug O
reactions O
not O
described O
above O
were O
reported* O
: O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
Vomiting B-OSE_Labeled_AE
NOS O
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
peritonitis B-OSE_Labeled_AE
, O
diverticular B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
Somnolence B-OSE_Labeled_AE
, O
hypoesthesia B-OSE_Labeled_AE
, O
polyneuropathy B-OSE_Labeled_AE
NOS O
, O
transient B-OSE_Labeled_AE
ischemic I-OSE_Labeled_AE
attack I-OSE_Labeled_AE
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
, I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
: O
Bronchitis B-OSE_Labeled_AE
NOS O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
: O
Mood B-OSE_Labeled_AE
alteration I-OSE_Labeled_AE
NOS O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
: O
Hypotension B-OSE_Labeled_AE
NOS O
, O
orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
Cardiac B-NonOSE_AE
disorders I-NonOSE_AE
: O
Bradycardia B-OSE_Labeled_AE
NOS O
Eye B-NonOSE_AE
disorders I-NonOSE_AE
: O
Blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
* O
All O
adverse O
reactions O
with O
> O
=3 O
% O
of O
patients O
in O
THALOMID/dexamethasone O
arm O
and O
with O
a O
> O
=1 O
% O
difference O
in O
proportion O
of O
patients O
between O
the O
THALOMID/dexamethasone O
arm O
compared O
to O
the O
placebo/dexamethasone O
arm O
. O

All O
grade O
3/4 O
and O
serious O
adverse O
reactions O
reported O
> O
2 O
patients O
in O
THALOMID/dexamethasone O
arm O
and O
with O
a O
percentage O
higher O
in O
the O
THALOMID/dexamethasone O
arm O
compared O
to O
the O
placebo/dexamethasone O
arm O
have O
been O
considered O
for O
possible O
inclusion O
. O

In O
any O
cases O
medical O
judgment O
has O
been O
applied O
for O
consideration O
of O
causality O
assessment O
. O

Adverse O
Reactions O
in O
Erythema O
Nodosum O
Leprosum O
( O
ENL O
) O
Clinical O
Trials O
Table O
4 O
lists O
treatment-emergent O
signs O
and O
symptoms O
that O
occurred O
in O
THALOMID-treated O
patients O
in O
clinical O
trials O
in O
ENL B-Not_AE_Candidate
. O

The O
most O
common O
adverse O
reactions O
( O
> O
=10 O
% O
) O
reported O
in O
patients O
with O
ENL O
were O
somnolence B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
. O

Doses O
ranged O
from O
50 O
to O
300 O
mg/day O
. O

All O
adverse O
reactions O
were O
mild O
to O
moderate O
in O
severity O
, O
and O
none O
resulted O
in O
discontinuation O
. O

Table O
4 O
: O
Summary O
of O
Adverse O
Events O
( O
AEs O
) O
Reported O
in O
Celgene-sponsored O
Controlled O
Clinical O
Trials O
Body O
System/Adverse O
Event O
All O
AEs O
Reportedin O
Patients O
with O
ENL O
AEs O
Reported O
in O
> O
=3 O
HIV-seropositive O
Patients O
Thalidomide O
Placebo O
50 O
to O
300 O
mg/day O
( O
N=24 O
) O
100 O
mg/day O
( O
N=36 O
) O
200 O
mg/day O
( O
N=32 O
) O
( O
N=35 O
) O
Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
0 O
8 O
( O
22.2 O
% O
) O
13 O
( O
40.6 O
% O
) O
10 O
( O
28.6 O
% O
) O
Anemia B-OSE_Labeled_AE
0 O
2 O
( O
5.6 O
% O
) O
4 O
( O
12.5 O
% O
) O
3 O
( O
8.6 O
% O
) O
Leukopenia B-OSE_Labeled_AE
0 O
6 O
( O
16.7 O
% O
) O
8 O
( O
25.0 O
% O
) O
3 O
( O
8.6 O
% O
) O
Lymphadenopathy B-OSE_Labeled_AE
0 O
2 O
( O
5.6 O
% O
) O
4 O
( O
12.5 O
% O
) O
3 O
( O
8.6 O
% O
) O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
16 O
( O
66.7 O
% O
) O
18 O
( O
50.0 O
% O
) O
19 O
( O
59.4 O
% O
) O
13 O
( O
37.1 O
% O
) O
Abdominal B-NonOSE_AE
pain I-NonOSE_AE
1 O
( O
4.2 O
% O
) O
1 O
( O
2.8 O
% O
) O
1 O
( O
3.1 O
% O
) O
4 O
( O
11.4 O
% O
) O
Accidental B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
2 O
( O
5.6 O
% O
) O
0 O
1 O
( O
2.9 O
% O
) O
Asthenia B-OSE_Labeled_AE
2 O
( O
8.3 O
% O
) O
2 O
( O
5.6 O
% O
) O
7 O
( O
21.9 O
% O
) O
1 O
( O
2.9 O
% O
) O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
2 O
( O
5.6 O
% O
) O
0 O
0 O
Chills B-NonOSE_AE
1 O
( O
4.2 O
% O
) O
0 O
3 O
( O
9.4 O
% O
) O
4 O
( O
11.4 O
% O
) O
Facial B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
0 O
0 O
0 O
Fever B-OSE_Labeled_AE
0 O
7 O
( O
19.4 O
% O
) O
7 O
( O
21.9 O
% O
) O
6 O
( O
17.1 O
% O
) O
Headache B-OSE_Labeled_AE
3 O
( O
12.5 O
% O
) O
6 O
( O
16.7 O
% O
) O
6 O
( O
18.7 O
% O
) O
4 O
( O
11.4 O
% O
) O
Infection B-OSE_Labeled_AE
0 O
3 O
( O
8.3 O
% O
) O
2 O
( O
6.3 O
% O
) O
1 O
( O
2.9 O
% O
) O
Malaise B-OSE_Labeled_AE
2 O
( O
8.3 O
% O
) O
0 O
0 O
0 O
Neck B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
0 O
0 O
0 O
Neck B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
0 O
0 O
0 O
Pain B-OSE_Labeled_AE
2 O
( O
8.3 O
% O
) O
0 O
1 O
( O
3.1 O
% O
) O
2 O
( O
5.7 O
% O
) O
Digestive B-NonOSE_AE
System I-NonOSE_AE
5 O
( O
20.8 O
% O
) O
16 O
( O
44.4 O
% O
) O
16 O
( O
50.0 O
% O
) O
15 O
( O
42.9 O
% O
) O
Anorexia B-OSE_Labeled_AE
0 O
1 O
( O
2.8 O
% O
) O
3 O
( O
9.4 O
% O
) O
2 O
( O
5.7 O
% O
) O
Constipation B-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
1 O
( O
2.8 O
% O
) O
3 O
( O
9.4 O
% O
) O
0 O
Diarrhea B-NonOSE_AE
1 O
( O
4.2 O
% O
) O
4 O
( O
11.1 O
% O
) O
6 O
( O
18.7 O
% O
) O
6 O
( O
17.1 O
% O
) O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
0 O
3 O
( O
8.3 O
% O
) O
3 O
( O
9.4 O
% O
) O
2 O
( O
5.7 O
% O
) O
Flatulence B-OSE_Labeled_AE
0 O
3 O
( O
8.3 O
% O
) O
0 O
2 O
( O
5.7 O
% O
) O
Liver B-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
multiple I-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
0 O
0 O
3 O
( O
9.4 O
% O
) O
0 O
Nausea B-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
0 O
4 O
( O
12.5 O
% O
) O
1 O
( O
2.9 O
% O
) O
Oral B-OSE_Labeled_AE
moniliasis I-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
4 O
( O
11.1 O
% O
) O
2 O
( O
6.3 O
% O
) O
0 O
Tooth B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
0 O
0 O
0 O
Metabolic B-NonOSE_AE
and I-NonOSE_AE
Endocrine I-NonOSE_AE
Disorders I-NonOSE_AE
1 O
( O
4.2 O
% O
) O
8 O
( O
22.2 O
% O
) O
12 O
( O
37.5 O
% O
) O
8 O
( O
22.9 O
% O
) O
Edema B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
3 O
( O
8.3 O
% O
) O
1 O
( O
3.1 O
% O
) O
0 O
Hyperlipemia B-OSE_Labeled_AE
0 O
2 O
( O
5.6 O
% O
) O
3 O
( O
9.4 O
% O
) O
1 O
( O
2.9 O
% O
) O
SGOT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
0 O
1 O
( O
2.8 O
% O
) O
4 O
( O
12.5 O
% O
) O
2 O
( O
5.7 O
% O
) O
Nervous B-NonOSE_AE
System I-NonOSE_AE
13 O
( O
54.2 O
% O
) O
19 O
( O
52.8 O
% O
) O
18 O
( O
56.3 O
% O
) O
12 O
( O
34.3 O
% O
) O
Agitation B-OSE_Labeled_AE
0 O
0 O
3 O
( O
9.4 O
% O
) O
0 O
Dizziness B-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
7 O
( O
19.4 O
% O
) O
6 O
( O
18.7 O
% O
) O
0 O
Insomnia B-OSE_Labeled_AE
0 O
0 O
3 O
( O
9.4 O
% O
) O
2 O
( O
5.7 O
% O
) O
Nervousness B-OSE_Labeled_AE
0 O
1 O
( O
2.8 O
% O
) O
3 O
( O
9.4 O
% O
) O
0 O
Neuropathy B-OSE_Labeled_AE
0 O
3 O
( O
8.3 O
% O
) O
0 O
0 O
Paresthesia B-OSE_Labeled_AE
0 O
2 O
( O
5.6 O
% O
) O
5 O
( O
15.6 O
% O
) O
4 O
( O
11.4 O
% O
) O
Somnolence B-OSE_Labeled_AE
9 O
( O
37.5 O
% O
) O
13 O
( O
36.1 O
% O
) O
12 O
( O
37.5 O
% O
) O
4 O
( O
11.4 O
% O
) O
Tremor B-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
0 O
0 O
0 O
Vertigo B-OSE_Labeled_AE
2 O
( O
8.3 O
% O
) O
0 O
0 O
0 O
Respiratory B-NonOSE_AE
System I-NonOSE_AE
3 O
( O
12.5 O
% O
) O
9 O
( O
25.0 O
% O
) O
6 O
( O
18.7 O
% O
) O
9 O
( O
25.7 O
% O
) O
Pharyngitis B-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
3 O
( O
8.3 O
% O
) O
2 O
( O
6.3 O
% O
) O
2 O
( O
5.7 O
% O
) O
Rhinitis B-NonOSE_AE
1 O
( O
4.2 O
% O
) O
0 O
0 O
4 O
( O
11.4 O
% O
) O
Sinusitis B-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
3 O
( O
8.3 O
% O
) O
1 O
( O
3.1 O
% O
) O
2 O
( O
5.7 O
% O
) O
Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
10 O
( O
41.7 O
% O
) O
17 O
( O
47.2 O
% O
) O
18 O
( O
56.3 O
% O
) O
19 O
( O
54.3 O
% O
) O
Acne B-OSE_Labeled_AE
0 O
4 O
( O
11.1 O
% O
) O
1 O
( O
3.1 O
% O
) O
0 O
Dermatitis B-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
2 O
( O
5.6 O
% O
) O
3 O
( O
9.4 O
% O
) O
0 O
Nail B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
0 O
1 O
( O
3.1 O
% O
) O
0 O
Pruritus B-NonOSE_AE
2 O
( O
8.3 O
% O
) O
1 O
( O
2.8 O
% O
) O
2 O
( O
6.3 O
% O
) O
2 O
( O
5.7 O
% O
) O
Rash B-NonOSE_AE
5 O
( O
20.8 O
% O
) O
9 O
( O
25.0 O
% O
) O
8 O
( O
25.0 O
% O
) O
11 O
( O
31.4 O
% O
) O
Rash B-OSE_Labeled_AE
maculopapular I-OSE_Labeled_AE
1 O
( O
4.2 O
% O
) O
6 O
( O
16.7 O
% O
) O
6 O
( O
18.7 O
% O
) O
2 O
( O
5.7 O
% O
) O
Sweating B-NonOSE_AE
0 O
0 O
4 O
( O
12.5 O
% O
) O
4 O
( O
11.4 O
% O
) O
Urogenital B-NonOSE_AE
System I-NonOSE_AE
2 O
( O
8.3 O
% O
) O
6 O
( O
16.7 O
% O
) O
2 O
( O
6.3 O
% O
) O
4 O
( O
11.4 O
% O
) O
Albuminuria B-OSE_Labeled_AE
0 O
3 O
( O
8.3 O
% O
) O
1 O
( O
3.1 O
% O
) O
2 O
( O
5.7 O
% O
) O
Hematuria B-OSE_Labeled_AE
0 O
4 O
( O
11.1 O
% O
) O
0 O
1 O
( O
2.9 O
% O
) O
Impotence B-OSE_Labeled_AE
2 O
( O
8.3 O
% O
) O
1 O
( O
2.8 O
% O
) O
0 O
0 O
Other O
Adverse O
Events O
Observed O
in O
ENL O
Patients O
THALOMID O
in O
doses O
up O
to O
400 O
mg/day O
has O
been O
administered O
investigationally O
in O
the O
United O
States O
over O
a O
19-year O
period O
in O
1465 O
patients O
with O
ENL B-Not_AE_Candidate
. O

The O
published O
literature O
describes O
the O
treatment O
of O
an O
additional O
1678 O
patients O
. O

To O
provide O
a O
meaningful O
estimate O
of O
the O
proportion O
of O
the O
individuals O
having O
adverse O
events O
, O
similar O
types O
of O
events O
were O
grouped O
into O
a O
smaller O
number O
of O
standardized O
categories O
using O
a O
modified O
COSTART O
dictionary/terminology O
. O

These O
categories O
are O
used O
in O
the O
listing O
below O
. O

All O
reported O
events O
are O
included O
except O
those O
already O
listed O
in O
the O
previous O
table O
. O

Due O
to O
the O
fact O
that O
these O
data O
were O
collected O
from O
uncontrolled O
studies O
, O
the O
incidence O
rate O
can O
not O
be O
determined O
. O

No O
causal O
relationship O
between O
THALOMID O
and O
these O
events O
can O
be O
conclusively O
determined O
at O
this O
time O
. O

These O
are O
reports O
of O
all O
adverse O
events O
noted O
by O
investigators O
in O
patients O
to O
whom O
they O
had O
administered O
thalidomide O
. O

Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
: O
ESR B-OSE_Labeled_AE
decrease I-OSE_Labeled_AE
, O
eosinophilia B-OSE_Labeled_AE
, O
granulocytopenia B-OSE_Labeled_AE
, O
hypochromic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
leukemia B-OSE_Labeled_AE
, O
leukocytosis B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
MCV B-OSE_Labeled_AE
elevated I-OSE_Labeled_AE
, O
RBC B-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
spleen B-OSE_Labeled_AE
palpable I-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
. O

Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
: O
Abdomen B-OSE_Labeled_AE
enlarged I-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
photosensitivity B-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
. O

Cardiovascular B-NonOSE_AE
System I-NonOSE_AE
: O
Bradycardia B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
vascular I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
, O
vasodilation B-OSE_Labeled_AE
. O

Digestive B-NonOSE_AE
System I-NonOSE_AE
: O
Anorexia B-OSE_Labeled_AE
, O
appetite B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
/ O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
enlarged B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
, O
eructation B-OSE_Labeled_AE
, O
flatulence B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
, O
intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
. O

Metabolic B-NonOSE_AE
and I-NonOSE_AE
Endocrine I-NonOSE_AE
: O
ADH B-OSE_Labeled_AE
inappropriate I-OSE_Labeled_AE
, O
amyloidosis B-OSE_Labeled_AE
, O
bilirubinemia B-OSE_Labeled_AE
, O
BUN B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
creatinine B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
cyanosis B-OSE_Labeled_AE
, O
diabetes B-OSE_Labeled_AE
, O
edema B-OSE_Labeled_AE
, O
electrolyte B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
hyperkalemia B-OSE_Labeled_AE
, O
hyperuricemia B-OSE_Labeled_AE
, O
hypocalcemia B-OSE_Labeled_AE
, O
hypoproteinemia B-OSE_Labeled_AE
, O
LDH B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
phosphorus B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
SGPT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
. O

Muscular B-NonOSE_AE
Skeletal I-NonOSE_AE
: O
Arthritis B-OSE_Labeled_AE
, O
bone B-OSE_Labeled_AE
tenderness I-OSE_Labeled_AE
, O
hypertonia B-OSE_Labeled_AE
, O
joint B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
leg B-OSE_Labeled_AE
cramps I-OSE_Labeled_AE
, O
myalgia B-OSE_Labeled_AE
, O
myasthenia B-OSE_Labeled_AE
, O
periosteal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
. O

Nervous B-NonOSE_AE
System I-NonOSE_AE
: O
Abnormal B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
amnesia B-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
causalgia B-OSE_Labeled_AE
, O
circumoral B-OSE_Labeled_AE
paresthesia I-OSE_Labeled_AE
, O
confusion B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
, O
euphoria B-OSE_Labeled_AE
, O
hyperesthesia B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
nervousness B-OSE_Labeled_AE
, O
neuralgia B-OSE_Labeled_AE
, O
neuritis B-OSE_Labeled_AE
, O
neuropathy B-OSE_Labeled_AE
, O
paresthesia B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
neuritis I-OSE_Labeled_AE
, O
psychosis B-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
System I-NonOSE_AE
: O
Cough B-OSE_Labeled_AE
, O
emphysema B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolus I-OSE_Labeled_AE
, O
rales B-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
voice B-OSE_Labeled_AE
alteration I-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
: O
Acne B-OSE_Labeled_AE
, O
alopecia B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
, O
eczematous B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
ichthyosis B-OSE_Labeled_AE
, O
perifollicular B-OSE_Labeled_AE
thickening I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
, O
seborrhea B-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
, O
vesiculobullous B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
. O

Special B-NonOSE_AE
Senses I-NonOSE_AE
: O
Amblyopia B-OSE_Labeled_AE
, O
deafness B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
eye I-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
tinnitus B-OSE_Labeled_AE
. O

Urogenital B-NonOSE_AE
: O
Decreased B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
clearance I-OSE_Labeled_AE
, O
hematuria B-OSE_Labeled_AE
, O
orchitis B-OSE_Labeled_AE
, O
proteinuria B-OSE_Labeled_AE
, O
pyuria B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
frequency I-OSE_Labeled_AE
. O

Other O
Adverse O
Events O
Observed O
in O
HIV-seropositive O
Patients O
In O
addition O
to O
controlled O
clinical O
trials O
, O
THALOMID O
has O
been O
used O
in O
uncontrolled O
studies O
in O
145 O
patients O
. O

Less O
frequent O
adverse O
events O
that O
have O
been O
reported O
in O
these O
HIV B-Not_AE_Candidate
- I-Not_AE_Candidate
seropositive I-Not_AE_Candidate
patients O
treated O
with O
THALOMID O
were O
grouped O
into O
a O
smaller O
number O
of O
standardized O
categories O
using O
modified O
COSTART O
dictionary/terminology O
and O
these O
categories O
are O
used O
in O
the O
listing O
below O
. O

Adverse O
events O
that O
have O
already O
been O
included O
in O
the O
tables O
and O
narrative O
above O
, O
or O
that O
are O
too O
general O
to O
be O
informative O
are O
not O
listed O
. O

Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
: O
Aplastic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
macrocytic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
megaloblastic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
microcytic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
. O

Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
: O
Ascites B-OSE_Labeled_AE
, O
AIDS B-OSE_Labeled_AE
, O
allergic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
and O
fever B-OSE_Labeled_AE
, O
cyst B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
CD I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
count I-OSE_Labeled_AE
, O
facial B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
flu B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
hernia B-OSE_Labeled_AE
, O
thyroid B-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
level I-OSE_Labeled_AE
altered I-OSE_Labeled_AE
, O
moniliasis B-OSE_Labeled_AE
, O
photosensitivity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
sarcoma B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
viral B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
. O

Cardiovascular B-NonOSE_AE
System I-NonOSE_AE
: O
Angina B-OSE_Labeled_AE
pectoris I-OSE_Labeled_AE
, O
arrhythmia B-OSE_Labeled_AE
, O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
bradycardia B-OSE_Labeled_AE
, O
cerebral B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
deep B-OSE_Labeled_AE
thrombophlebitis I-OSE_Labeled_AE
, O
heart B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
heart B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
murmur B-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarct I-OSE_Labeled_AE
, O
palpitation B-OSE_Labeled_AE
, O
pericarditis B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
vascular I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
postural B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
, O
thrombophlebitis B-OSE_Labeled_AE
, O
thrombosis B-OSE_Labeled_AE
. O

Digestive B-NonOSE_AE
System I-NonOSE_AE
: O
Cholangitis B-OSE_Labeled_AE
, O
cholestatic B-OSE_Labeled_AE
jaundice I-OSE_Labeled_AE
, O
colitis B-OSE_Labeled_AE
, O
dyspepsia B-OSE_Labeled_AE
, O
dysphagia B-OSE_Labeled_AE
, O
esophagitis B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
gum B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
, O
pancreatitis B-OSE_Labeled_AE
, O
parotid B-OSE_Labeled_AE
gland I-OSE_Labeled_AE
enlargement I-OSE_Labeled_AE
, O
periodontitis B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
, O
tooth B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
. O

Metabolic B-NonOSE_AE
and I-NonOSE_AE
Endocrine I-NonOSE_AE
: O
Avitaminosis B-OSE_Labeled_AE
, O
bilirubinemia B-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
, O
hypercholesterolemia B-OSE_Labeled_AE
, O
hypoglycemia B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
alkaline I-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
lipase I-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
. O

Muscular B-NonOSE_AE
Skeletal I-NonOSE_AE
: O
Myalgia B-OSE_Labeled_AE
, O
myasthenia B-OSE_Labeled_AE
. O

Nervous B-NonOSE_AE
System I-NonOSE_AE
: O
Abnormal B-OSE_Labeled_AE
gait I-OSE_Labeled_AE
, O
ataxia B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
libido I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
reflexes I-OSE_Labeled_AE
, O
dementia B-OSE_Labeled_AE
, O
dysesthesia B-OSE_Labeled_AE
, O
dyskinesia B-OSE_Labeled_AE
, O
emotional B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
, O
hostility B-OSE_Labeled_AE
, O
hypalgesia B-OSE_Labeled_AE
, O
hyperkinesia B-OSE_Labeled_AE
, O
incoordination B-OSE_Labeled_AE
, O
meningitis B-OSE_Labeled_AE
, O
neurologic B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
vertigo B-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
System I-NonOSE_AE
: O
Apnea B-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
, O
lung B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
lung B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
( O
including O
Pneumocystis B-OSE_Labeled_AE
carinii I-OSE_Labeled_AE
pneumonia I-OSE_Labeled_AE
) O
, O
rhinitis B-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
: O
Angioedema B-OSE_Labeled_AE
, O
benign B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
neoplasm I-OSE_Labeled_AE
, O
eczema B-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
simplex I-OSE_Labeled_AE
, O
incomplete O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
nail B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
psoriasis B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
. O

Special B-NonOSE_AE
Senses I-NonOSE_AE
: O
Conjunctivitis B-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
lacrimation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
retinitis B-OSE_Labeled_AE
, O
taste B-OSE_Labeled_AE
perversion I-OSE_Labeled_AE
. O

6.2 O
Postmarketing O
Experience O
The O
following O
additional O
adverse O
reactions O
have O
been O
identified O
during O
post O
approval O
use O
of O
THALOMID O
and O
are O
not O
already O
included O
in O
Clinical O
Trials O
Experience O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
: O
Decreased B-OSE_Labeled_AE
white I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
counts I-OSE_Labeled_AE
including O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
, O
changes B-OSE_Labeled_AE
in I-OSE_Labeled_AE
prothrombin I-OSE_Labeled_AE
time I-OSE_Labeled_AE
, O
pancytopenia B-OSE_Labeled_AE
, O
chronic B-OSE_Labeled_AE
myelogenous I-OSE_Labeled_AE
leukemia I-OSE_Labeled_AE
, O
nodular B-OSE_Labeled_AE
sclerosing I-OSE_Labeled_AE
Hodgkin I-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
erythroleukemia B-OSE_Labeled_AE
, O
lymphedema B-OSE_Labeled_AE
, O
lymphopenia B-OSE_Labeled_AE
. O

Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
: O
Hangover B-OSE_Labeled_AE
effect I-OSE_Labeled_AE
Cardiovascular B-NonOSE_AE
System I-NonOSE_AE
: O
Sick B-OSE_Labeled_AE
sinus I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
EKG B-OSE_Labeled_AE
abnormalities I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
. O

Digestive B-NonOSE_AE
System I-NonOSE_AE
: O
Intestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
, O
gastrointestinal B-OSE_Labeled_AE
perforations I-OSE_Labeled_AE
, O
bile B-OSE_Labeled_AE
duct I-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
, O
stomach B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
, O
aphthous B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
. O

Ear B-NonOSE_AE
and I-NonOSE_AE
Labyrinthine I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Hearing B-OSE_Labeled_AE
impairment I-OSE_Labeled_AE
. O

Immune B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Hypersensitivity B-OSE_Labeled_AE
. O

Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
: O
Severe O
infections B-OSE_Labeled_AE
( O
e.g. O
, O
fatal B-NonOSE_AE
sepsis B-OSE_Labeled_AE
including O
septic B-OSE_Labeled_AE
shock I-OSE_Labeled_AE
) O
and O
viral B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
( O
including O
varicella B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
, O
cytomegalovirus B-OSE_Labeled_AE
, O
and O
hepatitis B-OSE_Labeled_AE
B I-OSE_Labeled_AE
virus I-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
) O
. O

Metabolic B-NonOSE_AE
and I-NonOSE_AE
Endocrine I-NonOSE_AE
: O
Electrolyte B-OSE_Labeled_AE
imbalance I-OSE_Labeled_AE
including O
hypercalcemia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
and O
hypomagnesemia B-OSE_Labeled_AE
, O
hypothyroidism B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
alkaline I-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
, O
tumor B-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
myxedema B-OSE_Labeled_AE
. O

Nervous B-NonOSE_AE
System I-NonOSE_AE
: O
Changes B-OSE_Labeled_AE
in I-OSE_Labeled_AE
mental I-OSE_Labeled_AE
status I-OSE_Labeled_AE
or O
mood O
including O
suicide B-OSE_Labeled_AE
attempts I-OSE_Labeled_AE
, O
disturbances B-OSE_Labeled_AE
in I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
including O
lethargy B-OSE_Labeled_AE
, O
loss B-OSE_Labeled_AE
of I-OSE_Labeled_AE
consciousness I-OSE_Labeled_AE
or O
stupor B-OSE_Labeled_AE
, O
seizures B-OSE_Labeled_AE
including O
grand B-OSE_Labeled_AE
mal I-OSE_Labeled_AE
convulsions I-OSE_Labeled_AE
and O
status B-OSE_Labeled_AE
epilepticus I-OSE_Labeled_AE
, O
Parkinson B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
stroke B-OSE_Labeled_AE
, O
carpal B-OSE_Labeled_AE
tunnel I-OSE_Labeled_AE
, O
Raynaud B-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
migraine B-OSE_Labeled_AE
, O
foot B-OSE_Labeled_AE
drop I-OSE_Labeled_AE
. O

Renal B-NonOSE_AE
and I-NonOSE_AE
Urinary I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
oliguria B-OSE_Labeled_AE
, O
enuresis B-OSE_Labeled_AE
. O

Reproductive B-NonOSE_AE
System I-NonOSE_AE
and I-NonOSE_AE
Breast I-NonOSE_AE
Disorders I-NonOSE_AE
: O
amenorrhea B-OSE_Labeled_AE
, O
sexual B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
, O
galactorrhea B-OSE_Labeled_AE
, O
gynecomastia B-OSE_Labeled_AE
, O
metrorrhagia B-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
System I-NonOSE_AE
: O
Pleural B-OSE_Labeled_AE
effusion I-OSE_Labeled_AE
, O
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
: O
Erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
nodosum I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
purpura B-OSE_Labeled_AE
, O
petechiae B-OSE_Labeled_AE
. O

Special B-NonOSE_AE
Senses I-NonOSE_AE
: O
Diplopia B-OSE_Labeled_AE
, O
nystagmus B-OSE_Labeled_AE

